Early trial tests vaccine to train immune system against breast cancer
NCT ID NCT04270149
Summary
This is an early safety study testing a new type of vaccine for people with a common form of breast cancer (estrogen receptor-positive). The vaccine uses small pieces of protein (peptides) from the cancer to try to teach the body's immune system to recognize and fight the disease. The main goal is to see if the vaccine is safe and if it triggers an immune response, with the hope it could help prevent the cancer from coming back after standard treatments are finished.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.